PMC:7417114 / 36639-37254 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T199","span":{"begin":287,"end":295},"obj":"Body_part"},{"id":"T200","span":{"begin":420,"end":428},"obj":"Body_part"}],"attributes":[{"id":"A199","pred":"fma_id","subj":"T199","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A200","pred":"fma_id","subj":"T200","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"Using KINOMEscan biochemical kinase profiling assay data from the Harvard Medical School Library of Integrated Network-based Cellular Signatures (LINCS) (72) and data derived from the ChEMBL database, we focused on the ability of a list of FDA-approved kinase inhibitors to target those proteins implicated in SARS-CoV, MERS-CoV and related virus infections, as well as several unrelated viral infections, including ABL proteins, AAK1, AXL, CDK6, CDK9, CSK, EGFR, FYN, GAK, KIT, LYN, RET, SRC, and YES (Table 2, Fig. 3).\nFigure 3. Repurposing of kinase inhibitors as antiviral therapies and for respiratory benefit."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T393","span":{"begin":310,"end":318},"obj":"Disease"},{"id":"T394","span":{"begin":341,"end":357},"obj":"Disease"},{"id":"T395","span":{"begin":388,"end":404},"obj":"Disease"},{"id":"T396","span":{"begin":416,"end":419},"obj":"Disease"}],"attributes":[{"id":"A393","pred":"mondo_id","subj":"T393","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A394","pred":"mondo_id","subj":"T394","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A395","pred":"mondo_id","subj":"T395","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A396","pred":"mondo_id","subj":"T396","obj":"http://purl.obolibrary.org/obo/MONDO_0008692"}],"text":"Using KINOMEscan biochemical kinase profiling assay data from the Harvard Medical School Library of Integrated Network-based Cellular Signatures (LINCS) (72) and data derived from the ChEMBL database, we focused on the ability of a list of FDA-approved kinase inhibitors to target those proteins implicated in SARS-CoV, MERS-CoV and related virus infections, as well as several unrelated viral infections, including ABL proteins, AAK1, AXL, CDK6, CDK9, CSK, EGFR, FYN, GAK, KIT, LYN, RET, SRC, and YES (Table 2, Fig. 3).\nFigure 3. Repurposing of kinase inhibitors as antiviral therapies and for respiratory benefit."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T465","span":{"begin":204,"end":211},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"},{"id":"T466","span":{"begin":230,"end":231},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T467","span":{"begin":341,"end":346},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T468","span":{"begin":469,"end":472},"obj":"http://purl.obolibrary.org/obo/CLO_0037126"},{"id":"T469","span":{"begin":489,"end":492},"obj":"http://purl.obolibrary.org/obo/CLO_0009132"}],"text":"Using KINOMEscan biochemical kinase profiling assay data from the Harvard Medical School Library of Integrated Network-based Cellular Signatures (LINCS) (72) and data derived from the ChEMBL database, we focused on the ability of a list of FDA-approved kinase inhibitors to target those proteins implicated in SARS-CoV, MERS-CoV and related virus infections, as well as several unrelated viral infections, including ABL proteins, AAK1, AXL, CDK6, CDK9, CSK, EGFR, FYN, GAK, KIT, LYN, RET, SRC, and YES (Table 2, Fig. 3).\nFigure 3. Repurposing of kinase inhibitors as antiviral therapies and for respiratory benefit."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T325","span":{"begin":260,"end":270},"obj":"Chemical"},{"id":"T326","span":{"begin":287,"end":295},"obj":"Chemical"},{"id":"T327","span":{"begin":416,"end":419},"obj":"Chemical"},{"id":"T328","span":{"begin":420,"end":428},"obj":"Chemical"},{"id":"T329","span":{"begin":553,"end":563},"obj":"Chemical"},{"id":"T330","span":{"begin":567,"end":576},"obj":"Chemical"}],"attributes":[{"id":"A325","pred":"chebi_id","subj":"T325","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A326","pred":"chebi_id","subj":"T326","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A327","pred":"chebi_id","subj":"T327","obj":"http://purl.obolibrary.org/obo/CHEBI_30805"},{"id":"A328","pred":"chebi_id","subj":"T328","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A329","pred":"chebi_id","subj":"T329","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A330","pred":"chebi_id","subj":"T330","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"Using KINOMEscan biochemical kinase profiling assay data from the Harvard Medical School Library of Integrated Network-based Cellular Signatures (LINCS) (72) and data derived from the ChEMBL database, we focused on the ability of a list of FDA-approved kinase inhibitors to target those proteins implicated in SARS-CoV, MERS-CoV and related virus infections, as well as several unrelated viral infections, including ABL proteins, AAK1, AXL, CDK6, CDK9, CSK, EGFR, FYN, GAK, KIT, LYN, RET, SRC, and YES (Table 2, Fig. 3).\nFigure 3. Repurposing of kinase inhibitors as antiviral therapies and for respiratory benefit."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1304","span":{"begin":416,"end":419},"obj":"Gene"},{"id":"1305","span":{"begin":430,"end":434},"obj":"Gene"},{"id":"1306","span":{"begin":436,"end":439},"obj":"Gene"},{"id":"1307","span":{"begin":441,"end":445},"obj":"Gene"},{"id":"1308","span":{"begin":447,"end":451},"obj":"Gene"},{"id":"1309","span":{"begin":453,"end":456},"obj":"Gene"},{"id":"1310","span":{"begin":458,"end":462},"obj":"Gene"},{"id":"1311","span":{"begin":464,"end":467},"obj":"Gene"},{"id":"1312","span":{"begin":469,"end":472},"obj":"Gene"},{"id":"1313","span":{"begin":474,"end":477},"obj":"Gene"},{"id":"1314","span":{"begin":479,"end":482},"obj":"Gene"},{"id":"1315","span":{"begin":484,"end":487},"obj":"Gene"},{"id":"1316","span":{"begin":310,"end":318},"obj":"Species"},{"id":"1317","span":{"begin":320,"end":328},"obj":"Species"},{"id":"1318","span":{"begin":341,"end":357},"obj":"Disease"},{"id":"1319","span":{"begin":388,"end":404},"obj":"Disease"}],"attributes":[{"id":"A1304","pred":"tao:has_database_id","subj":"1304","obj":"Gene:25"},{"id":"A1305","pred":"tao:has_database_id","subj":"1305","obj":"Gene:22848"},{"id":"A1306","pred":"tao:has_database_id","subj":"1306","obj":"Gene:558"},{"id":"A1307","pred":"tao:has_database_id","subj":"1307","obj":"Gene:1021"},{"id":"A1308","pred":"tao:has_database_id","subj":"1308","obj":"Gene:1025"},{"id":"A1309","pred":"tao:has_database_id","subj":"1309","obj":"Gene:1445"},{"id":"A1310","pred":"tao:has_database_id","subj":"1310","obj":"Gene:1956"},{"id":"A1311","pred":"tao:has_database_id","subj":"1311","obj":"Gene:2534"},{"id":"A1312","pred":"tao:has_database_id","subj":"1312","obj":"Gene:2580"},{"id":"A1313","pred":"tao:has_database_id","subj":"1313","obj":"Gene:3815"},{"id":"A1314","pred":"tao:has_database_id","subj":"1314","obj":"Gene:4067"},{"id":"A1315","pred":"tao:has_database_id","subj":"1315","obj":"Gene:5979"},{"id":"A1316","pred":"tao:has_database_id","subj":"1316","obj":"Tax:694009"},{"id":"A1317","pred":"tao:has_database_id","subj":"1317","obj":"Tax:1335626"},{"id":"A1318","pred":"tao:has_database_id","subj":"1318","obj":"MESH:D001102"},{"id":"A1319","pred":"tao:has_database_id","subj":"1319","obj":"MESH:D001102"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Using KINOMEscan biochemical kinase profiling assay data from the Harvard Medical School Library of Integrated Network-based Cellular Signatures (LINCS) (72) and data derived from the ChEMBL database, we focused on the ability of a list of FDA-approved kinase inhibitors to target those proteins implicated in SARS-CoV, MERS-CoV and related virus infections, as well as several unrelated viral infections, including ABL proteins, AAK1, AXL, CDK6, CDK9, CSK, EGFR, FYN, GAK, KIT, LYN, RET, SRC, and YES (Table 2, Fig. 3).\nFigure 3. Repurposing of kinase inhibitors as antiviral therapies and for respiratory benefit."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T143","span":{"begin":253,"end":270},"obj":"http://purl.obolibrary.org/obo/GO_0033673"},{"id":"T144","span":{"begin":388,"end":404},"obj":"http://purl.obolibrary.org/obo/GO_0016032"},{"id":"T145","span":{"begin":458,"end":462},"obj":"http://purl.obolibrary.org/obo/GO_0005006"},{"id":"T146","span":{"begin":546,"end":563},"obj":"http://purl.obolibrary.org/obo/GO_0033673"}],"text":"Using KINOMEscan biochemical kinase profiling assay data from the Harvard Medical School Library of Integrated Network-based Cellular Signatures (LINCS) (72) and data derived from the ChEMBL database, we focused on the ability of a list of FDA-approved kinase inhibitors to target those proteins implicated in SARS-CoV, MERS-CoV and related virus infections, as well as several unrelated viral infections, including ABL proteins, AAK1, AXL, CDK6, CDK9, CSK, EGFR, FYN, GAK, KIT, LYN, RET, SRC, and YES (Table 2, Fig. 3).\nFigure 3. Repurposing of kinase inhibitors as antiviral therapies and for respiratory benefit."}

{"project":"LitCovid-sentences","denotations":[{"id":"T284","span":{"begin":0,"end":520},"obj":"Sentence"},{"id":"T285","span":{"begin":521,"end":530},"obj":"Sentence"},{"id":"T286","span":{"begin":531,"end":615},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Using KINOMEscan biochemical kinase profiling assay data from the Harvard Medical School Library of Integrated Network-based Cellular Signatures (LINCS) (72) and data derived from the ChEMBL database, we focused on the ability of a list of FDA-approved kinase inhibitors to target those proteins implicated in SARS-CoV, MERS-CoV and related virus infections, as well as several unrelated viral infections, including ABL proteins, AAK1, AXL, CDK6, CDK9, CSK, EGFR, FYN, GAK, KIT, LYN, RET, SRC, and YES (Table 2, Fig. 3).\nFigure 3. Repurposing of kinase inhibitors as antiviral therapies and for respiratory benefit."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T2198","span":{"begin":40,"end":122},"obj":"CHEBI:35222;CHEBI:35222"}],"text":"Using KINOMEscan biochemical kinase profiling assay data from the Harvard Medical School Library of Integrated Network-based Cellular Signatures (LINCS) (72) and data derived from the ChEMBL database, we focused on the ability of a list of FDA-approved kinase inhibitors to target those proteins implicated in SARS-CoV, MERS-CoV and related virus infections, as well as several unrelated viral infections, including ABL proteins, AAK1, AXL, CDK6, CDK9, CSK, EGFR, FYN, GAK, KIT, LYN, RET, SRC, and YES (Table 2, Fig. 3).\nFigure 3. Repurposing of kinase inhibitors as antiviral therapies and for respiratory benefit."}